Clinical Trials Logo

AML, Adult clinical trials

View clinical trials related to AML, Adult.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04614636 Terminated - Multiple Myeloma Clinical Trials

FT538 in Subjects With Advanced Hematologic Malignancies

Start date: October 17, 2020
Phase: Phase 1
Study type: Interventional

This is a Phase I dose-finding study of FT538 as monotherapy in acute myeloid leukemia (AML) and in combination with monoclonal antibodies in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

NCT ID: NCT04496999 Terminated - AML, Adult Clinical Trials

HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt.

HDMM
Start date: July 13, 2020
Phase: Phase 1
Study type: Interventional

This is a non-randomized prospective open-label single-arm clinical phase I trial investigating dose finding, feasibility and safety of the combined treatment of HDM201 and midostaurin in patients with relapsed/refractory acute myeloid leukemia (AML) with FLT3mut applying an accelerated titration design.

NCT ID: NCT04425655 Terminated - AML Clinical Trials

Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.

Start date: August 5, 2020
Phase: Phase 2
Study type: Interventional

This phase 2 clinical trial will evaluate the effectiveness and safety of fludarabine in combination with CPX-351 in patients with untreated AML. Patients will receive fludarabine and CPX-351 during Induction 1 and 2 as well as 2 cycles of consolidation therapy.

NCT ID: NCT04079738 Terminated - AML Clinical Trials

Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib

Start date: September 20, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase I/II study augmenting TAK-659 action in relapsed/refractory AML by addition of the proteasome inhibitor Ixazomib. Phase I of the study will determine the safety, tolerability, and maximum tolerated dose (MTD) of the combination of TAK-659 and Ixazomib. During the phase I, dose escalation will be conducted according to a standard 3+3 dose escalation schema, and up to 18 response-evaluable patients will be enrolled. Phase II of the study will evaluate the efficacy of the combination by measuring the overall response rate (ORR).